Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis
- PMID: 16482643
Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis
Abstract
Objective: To begin the validation process of the preliminary criteria for inactive disease (ID), clinical remission on medication (CRM), and clinical remission off medication (CR) in children with select forms of juvenile idiopathic arthritis (JIA).
Methods: We used the OMERACT filter paradigm to estimate the validity of the criteria within each of the filter's 3 components: truth, discrimination, and feasibility, in 5 categories of JIA: systemic arthritis, persistent and extended oligoarthritis, and rheumatoid factor-positive and negative polyarthritis. Data sources for determining validity estimates included a Delphi questionnaire survey sent to 246 pediatric rheumatologists in 34 countries, a consensus conference attended by 20 senior pediatric rheumatologists representing 9 countries, a retrospective chart review of 437 patients with JIA from 3 tertiary care clinics who had been followed between 4 and 22 years, and the literature.
Results: Truth component: face and content validity. These aspects of validity were largely established via the Delphi questionnaire exercise and the consensus conference. Using an 80% consensus level, participants felt that a set of non-redundant variables could effectively differentiate the clinical states of ID, CRM, and CR. Criterion validity could not be irrefutably established because no gold standard for inactive disease exists for JIA. As an alternative, published investigations of remission in JIA were used to estimate concurrent and convergent validity, as surrogates for criterion validity and as indicators of overall construct validity. Correlational analyses revealed the new criteria to have good construct validity. Discrimination component: the criteria demonstrated moderate to high levels of classification, prognosis, and responsiveness (sensitivity to change) using data from the chart review. Patients who were able to attain CR remained disease-free for substantially longer periods than did those who attained only ID or CRM. Responsiveness was evidenced by the ability of the criteria to allow movement of most patients between the disease states, consistent with what is known of the course of the disease. Feasibility component: Results of the Delphi and consensus conference produced a set of criteria that are easily, quickly, and inexpensively completed in the physician's office, and present minimal or no risk to the patient.
Conclusion: The preliminary criteria demonstrated moderate to excellent validity characteristics in some, but not all components of the OMERACT filter. Prospective validation studies are under way.
Similar articles
-
Patterns of clinical remission in select categories of juvenile idiopathic arthritis.Arthritis Rheum. 2005 Nov;52(11):3554-62. doi: 10.1002/art.21389. Arthritis Rheum. 2005. PMID: 16255044
-
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis.Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36. doi: 10.1002/acr.20497. Arthritis Care Res (Hoboken). 2011. PMID: 21717596
-
Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases.J Rheumatol. 2009 Jul;36(7):1532-5. doi: 10.3899/jrheum.080434. Epub 2009 Jun 1. J Rheumatol. 2009. PMID: 19487265
-
Developing outcome measures for paediatric rheumatic diseases.Best Pract Res Clin Rheumatol. 2009 Oct;23(5):609-24. doi: 10.1016/j.berh.2009.07.001. Best Pract Res Clin Rheumatol. 2009. PMID: 19853827 Review.
-
Outcome following onset of juvenile idiopathic inflammatory arthritis: I. frequency of different outcomes.Rheumatology (Oxford). 2005 Aug;44(8):995-1001. doi: 10.1093/rheumatology/keh620. Epub 2005 Apr 12. Rheumatology (Oxford). 2005. PMID: 15827045 Review.
Cited by
-
How common is remission in juvenile idiopathic arthritis: A systematic review.Semin Arthritis Rheum. 2017 Dec;47(3):331-337. doi: 10.1016/j.semarthrit.2017.05.007. Epub 2017 May 20. Semin Arthritis Rheum. 2017. PMID: 28625712 Free PMC article.
-
Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.Paediatr Drugs. 2019 Dec;21(6):469-492. doi: 10.1007/s40272-019-00362-6. Paediatr Drugs. 2019. PMID: 31673960 Free PMC article.
-
Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.Paediatr Drugs. 2011 Jun 1;13(3):161-73. doi: 10.2165/11588140-000000000-00000. Paediatr Drugs. 2011. PMID: 21500870 Review.
-
American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus.Arthritis Care Res (Hoboken). 2018 Jun;70(6):813-822. doi: 10.1002/acr.23557. Epub 2018 Apr 25. Arthritis Care Res (Hoboken). 2018. PMID: 29693328 Free PMC article.
-
Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.Paediatr Drugs. 2012 Feb 1;14(1):7-12. doi: 10.2165/11595980-000000000-00000. Paediatr Drugs. 2012. PMID: 22149548 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials